Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial

Frontiers in Immunology(2021)10.3389/fimmu.2021.694759Source: DataRank Database

Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial is a research paper published in Frontiers in Immunology (2021). On theSindex it has a DataRank of 1.2. It has been cited 42 times, with 30 citing works in its 1-hop citation network.

N/A

1.2DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access42 citations · 30 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02532049

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 5.34)OA: goldTopics (68)Linked Datasets (6)DataCite Reuse (6)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 47%Citation Network 53%

Base Score Contribution

0.564

From this paper's citation signal

Citation Network Contribution

0.631

From 26 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 30 citers.

mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
npj Vaccines202256 citations38 referencesContributes 0.106
Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity
Frontiers in Immunology202230 citations64 referencesContributes 0.054
Structural analysis of Plasmodium falciparum ookinete surface antigen Pfs28 relevant for malaria vaccine design
Scientific Reports202210 citations45 referencesContributes 0.053
Plasmodium parasitophorous vacuole membrane protein Pfs16 promotes malaria transmission by silencing mosquito immunity
Journal of Biological Chemistry202313 citations50 referencesContributes 0.053
Quantifying Reductions in Plasmodium falciparum Infectivity to Mosquitos: A Sample Size Calculator to Inform Clinical Trials on Transmission-Reducing Interventions
Frontiers in Immunology202214 citations58 referencesContributes 0.047

Authors (28)

Ruth Payne ORCID,Iona J. Taylor ORCID,Kazutoyo Miura ORCID,Carol A. Long,Sean C. Elias ORCID

Live enrichment

PubMed:34335606 PMC:PMC8318801 OpenAlex:https://openalex.org/W3177637593

National Institute for Health Research (NIHR)

Grant: CL-2019-26-001

Wellcome Trust

Grant: 106917/Z/15/Z

National Institute for Health Research (NIHR)

Grant: NIHR201409

European Commission

Grant: 305282

A Multi-Stage Malaria Vaccine

Wellcome Trust

Grant: 106917

Harnessing Human Antibodies to Deliver Effective Immunoprophylaxis against Difficult Disease Targets.

FWCI

5.34

Citation Percentile

1.0%

Citation Trend

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.694759/pdf

GOLDhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.694759/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.694759/pdf

publisherhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.694759/full

journalhttps://doi.org/10.3389/fimmu.2021.694759

Fields of Study

Virus-based gene therapy researchMalaria Research and ControlMosquito-borne diseases and controlMedicineBiology0301 basic medicine03 medical and health sciencesAntibodies, ProtozoanCells, CulturedEnglandHealthy VolunteersHumansImmunizationImmunogenicity, VaccineMalaria VaccinesMalaria, FalciparumPlasmodium falciparumT-LymphocytesTime FactorsVaccines, Synthetic

MeSH Terms

Immunogenicity, VaccineAntibodies, ProtozoanCells, CulturedEnglandHumansImmunizationPlasmodium falciparumT-LymphocytesTime FactorsVaccines, SyntheticMalaria, FalciparumMalaria VaccinesHealthy Volunteers

Keywords

ImmunogenicityVirologyReactogenicityAntigenMalariaVacciniaPlasmodium falciparumVector (molecular biology)Modified vaccinia AnkaraMedicineAntibodyMalaria vaccineViral vectorImmunologyBiologyRecombinant DNAVaccineTransmission-blockingPfs25Imx313Vaccines, SyntheticTime FactorsT-Lymphocytes610Antibodies, ProtozoanRC581-607Healthy VolunteersImmunogenicity, VaccineEnglandMalaria VaccinesHumansImmunizationImmunologic diseases. AllergyMalaria, FalciparumCells, Cultured

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Additional file 1 of Characterization of PSOP26 as an ookinete surface antigen with improved transmission-blocking activity when fused with PSOP25

10.6084/m9.figshare.19845689.v1figshare

Additional file 1 of Characterization of PSOP26 as an ookinete surface antigen with improved transmission-blocking activity when fused with PSOP25

10.6084/m9.figshare.19845689figshare

Additional file 2 of Characterization of PSOP26 as an ookinete surface antigen with improved transmission-blocking activity when fused with PSOP25

10.6084/m9.figshare.19845692.v1figshare

Additional file 2 of Characterization of PSOP26 as an ookinete surface antigen with improved transmission-blocking activity when fused with PSOP25

10.6084/m9.figshare.19845692figshare

Additional file 3 of Characterization of PSOP26 as an ookinete surface antigen with improved transmission-blocking activity when fused with PSOP25

10.6084/m9.figshare.19845695.v1figshare